Navigation Links
AAP Initiates Public Relations Effort to Counter Bad Vaccine Publicity
Date:2/15/2008

National Autism Association Requests AAP Instead Focus on Removing Unnecessary Toxins From Vaccines and Providing Medical Treatments for Children with Autism

CHICAGO, Feb. 15 /PRNewswire-USNewswire/ -- The American Academy of Pediatrics (AAP) has initiated a "parent spokesperson" campaign to counter recent negative publicity surrounding toxins in vaccines, requesting parent vaccine proponents to conduct media interviews as "part of our ongoing response to media stories regarding autism and vaccines."

The negative publicity stems from long-standing reports from thousands of parents that the mercury-based vaccine preservative thimerosal contributed to their children's regressive autism. In 1999, the AAP issued a statement requesting the toxin be phased out of vaccines, but has since continued supporting its use as a preservative, even fighting against legislation in several states which would ban the poison from children's vaccines.

Although the mercury content in many vaccines on the current schedule has been reduced to trace amounts, these trace amounts are not regulated by the FDA. Large doses of mercury still remain in some vaccines, including flu shots. Other highly toxic substances including aluminum remain as well.

Parent advocates for children's health believe the AAP should direct their resources towards increasing the safety of vaccines, rather than damage-control media campaigns and attempts to censor fictional TV shows such as ABC's "Eli Stone." "Their resources are so valuable," says Rita Shreffler, parent and Executive Director of NAA. "It is my hope that the AAP will stop defending the continued use of poison in vaccines and instead direct that energy towards implementing promising medical treatments that have thus far been denied to the vast number of children diagnosed with autism. In the last several years, we have come to know that improvement and even recovery from autism is possible when children receive
'/>"/>

SOURCE National Autism Association
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Tyco International Increases Quarterly Dividend 36 Percent to 15 Cents per Share; Initiates New $1 Billion Share Repurchase Program
2. Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership
3. Vista Partners Initiates Coverage on Raptor Pharmaceuticals Corp.
4. GenPrime Initiates External Clinical Trials of its Bacterial Contamination Test for Rapid Detection of Bacteria in Platelets
5. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
6. Harbinger Research Initiates Coverage on HearAtLast
7. Wyeth Consumer Healthcare Initiates Voluntary Recall and Replacement Program for Several Robitussin Products and Childrens Dimetapp Cold & Chest Congestion
8. MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma
9. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
10. Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent
11. Isolagen Initiates Phase III Clinical Program to Investigate Isolagen Therapy(TM) for the Treatment of Acne Scars
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2008)...Michigan received $5 million from the National Ins...esource of high-quality experimental data sets of ...mputer-aided drug design to a new level. , The ...puter programs that can predict the effectiveness ...ciate professor in the U-M College of Pharmacy and...
(Date:10/10/2008)... Johns Hopkins University School,of Medicine is la...ptimizing Adjuvant Breast Cancer Strategies: From ...ent key research data on the latest advances in,br...ents in the treatment of breast cancer have,led to...ons that are,increasingly tailored to the specific...
(Date:10/10/2008)... The Mobile Massage Team, (http://www.mobilemassag...massage,services for corporate wellness programs, ... today that it is expanding its service area throu...lphia metropolitan region., "We are quite excited...ed, massage programs and services throughout both...
(Date:10/10/2008)...nationally recognized faculty will,present the ver...east,cancer in the multimedia course "Optimizing A...to Treatment Selection" during National Breast,Can...icing oncologists and other interested,health care...t care,advances. This accredited course offers con...
Breaking Medicine News(10 mins):Health News:U-M to house leading drug database 2Health News:Latest Research on Breast Cancer Presented in a Virtual E-Conference CME Course 2Health News:Mobile Massage Team Announces Expansion of On-Site Seated Massage Services Throughout Eastern Pennsylvania and the Greater Philadelphia Region 2Health News:Nationally Recognized Faculty Presents Latest Advances in Care of Patients with Breast Cancer 2
...n Eye Care Hospitals, one of the largest eye care ...its first branch here, with seven more in the offi...boration with K. Premraj, a prominent ophthalmic s...r of Prems' Eye Clinic. The first facility would h...
...on Americans have hypertension, that is, blood pre...n 120/80 mmHg). If untreated, it can lead to heart...anges are the first-stage treatment for the diseas...rescribed. Many patients with high blood pressure...
..., Dr Mukesh Haikerwal, today launched a unique web...//suffering fatigue, and make hospitals safer for ...Assessment website allows doctors to track their w...ng hours over a week, and determine whether their ...
...ent research published in The Lancet states that, ...y could help in faster information processing and ...emonstrated the effects of reduced levels of folat...omocysteine, in the blood of older adults which re...
Other Medicine News:Health News:Chinese Herb Shows Promise In Reducing Hypertension 2Health News:New AMA Tool Empowers Doctors to Work Safer Hours 2
(Date:10/8/2008)...ment in patients with pulmonary arterial hype...ve limited benefit for this debilitating, rap...e, -- Imatinib mesylate, available as Gleevec(R...inhibit protein associated with PAH, -- Novarti...e in PAH in 2009 EAST HANOVER, N.J., Oct. 8 ...
(Date:10/7/2008)...exas Cardiac Arrhythmia,Institute (TCAI) at St. Da...nly a few sites in the nation to participate in an...reat persistent atrial fibrillation. TCAI, an,inte...specializing in heart,rhythm disorders, is a partn...s Cardiovascular Consultants., "This is just anot...
(Date:10/7/2008)...-- CEL-SCI Corporation,(NYSE: CVM ) announced tod...reement (MTA) with the National Institutes of Heal...r. Francesco M. Marincola, M.D., to,investigate th...ironment,caused by CEL-SCI,s cancer drug Multikine...ease and Immunogentics Section, Department of Tran...
(Date:10/7/2008)...ligen Therapeutics Inc.,today announced that in vi...dates were presented at the XXII International Com...ighlighted the candidates, efficacy in,several ani...se highlighted presentations, as well as several i...l the deep expertise and expanding,knowledge base ...
Breaking Medicine Technology:Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 2Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 3Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 4Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 5Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 6Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 7Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 8Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 9Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 10Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 11Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 12Texas Cardiac Arrhythmia Institute at St. David's Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation 2CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 2CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 3In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 2In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 3In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 4Finding the source 3A Cells that initiate a common infant tumor identified 21225 1Brain Stem Cells Reverse Myelin Deficiency in Mice 21223 1Brain Stem Cells Reverse Myelin Deficiency in Mice 21223 2Brain Stem Cells Reverse Myelin Deficiency in Mice 21223 3Impact of Rising Gas Food Prices Felt Globally 21221 1Impact of Rising Gas Food Prices Felt Globally 21221 2Pioneering Safe Medication Return Initiative Reviewed During Pharmaceutical Disposal Summit 21219 1Pioneering Safe Medication Return Initiative Reviewed During Pharmaceutical Disposal Summit 21219 2
... ONCONASE for,Treatment of Neuroblastoma, BLOOMFIE...Alfacell Corporation today announced that new data... is active against naive and,chemoresistant neurob...vivo data published in Cancer,Letters (2007; Vol. ...ween Alfacell and Martin Michaelis, M.D., Ph.D., a...
...p; CEO of the Lupus,Foundation of America, Inc., W...- The Lupus,Foundation of America, Inc. and more t...iting the preliminary findings of the Phase,III cl...nt for,lupus kidney disease being tested by Asprev...ments for lupus patients is,critical because many ...
Other Medicine Technology:In Vitro and In Vivo Data Show Alfacell's Onocanse is Active,Against Naive and Chemoresistant Neuroblastoma Cells 2In Vitro and In Vivo Data Show Alfacell's Onocanse is Active,Against Naive and Chemoresistant Neuroblastoma Cells 3Lupus Foundation of America Statement on Results for Clinical Study,of CellCept Released by Aspreva Pharmaceutical Company 2
...s is a national reference laboratory and a worldwi...velopment. ARUP offers an extensive test menu of h... and anatomic pathology. Owned by the University o...an half of the nation's university teaching hospit...
...s is a national reference laboratory and a worldwi...velopment. ARUP offers an extensive test menu of h... and anatomic pathology. Owned by the University o...an half of the nation's university teaching hospit...
...s is a national reference laboratory and a worldwi...velopment. ARUP offers an extensive test menu of h... and anatomic pathology. Owned by the University o...an half of the nation's university teaching hospit...
...s is a national reference laboratory and a worldwi...velopment. ARUP offers an extensive test menu of h... and anatomic pathology. Owned by the University o...an half of the nation's university teaching hospit...
Medicine Products: